pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›GAZYVA
drug
save

GAZYVA

updated 6mo ago
by Genentech Inc
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval56 co-mentions · 14 sources
  • drugobinutuzumab56 co-mentions · 14 sources

all catalysts(0)

nothing on the calendar yet

Trials studying GAZYVA

  • phase2Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignanciesrecruitingn=150
  • phase3A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritisactive not recruitingn=271
  • phase3A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphomaactive not recruitingn=799
  • phase3Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)active not recruitingn=652
  • phase2A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participantsrecruitingn=40
  • phase2An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphomaactive not recruitingn=211
  • phase3A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphomaactive not recruitingn=270
  • phase3A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathyactive not recruitingn=142

News(3)

  • Novo revamps its direct-to-consumer platform; Roche drug Gazyva approved again
    Plus news about Uniquity Bio, Commit Biologics, Rosemont Pharmaceuticals, Aytu and Aclaris Therapeutics. Novo relaunches NovoCare direct-to-consumer platform: Novo is revamping its DTC business wit…
    endpoints · 2d ago
  • Unlocking cell surface protein research with site-specific labeling
    Applications in flow cytometry, cell sorting, target validation, and therapeutic discovery
    biospace · 2mo ago
  • Beeline flies into phase 3 as oral lupus drug soars past placebo
    A phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.
    fiercebiotech · 2mo ago
brand
GAZYVA
generic
OBINUTUZUMAB
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?